The head of the World Health Organization (WHO), Tedros
Adhanom Ghebreyesus, has unveiled plans to speed up the
licensing and use of effective novel vaccines against
tuberculosis (TB), the second leading infectious killer
after COVID-19 and the 13th leading cause of death
worldwide.
Tedros announced
the creation of the TB Vaccine Accelerator Council at a
high-level panel at the World Economic Forum in Davos,
Switzerland.
During his opening remarks, he noted that
one of the most important lessons from the COVID-19 response
is that innovative health interventions can be delivered
fast if they are prioritized politically and financed
adequately: no new TB vaccines have been licensed in a
century, despite its impact on human health.
“The
challenges presented by TB and COVID-19 are different, but
the ingredients that accelerate science, research and
innovation are the same: urgent, up-front public investment;
support from philanthropy; and engagement of the private
sector and communities,” said Tedros. “We believe the TB
field will benefit from similar high-level
coordination.”
No slowing down
The new
Council is intended to bring together funders, global
agencies, governments and those with TB, in identifying and
overcoming barriers to vaccine development.
TB,
also known as consumption, is caused by bacteria that mostly
affect the lungs. It is spread through the air when someone
who has TB coughs, sneezes or spits.
The disease is
both curable and preventable, yet, despite global
commitments to end TB by 2030, the epidemic shows no sign of
slowing down, says WHO.
In
2021, roughly 10.6 million fell sick with the disease, and
1.6 million died from it. Drug resistance continues to be a
major problem, with close to half a million people
developing drug-resistant TB every year.
A sole
vaccine
Currently, the Bacillus Calmette-Guérin
(BCG) vaccine, developed in 1921, is the only licensed TB
vaccine. While BCG provides moderate efficacy in preventing
severe forms of TB in infants and young children, it does
not adequately protect adolescents and adults, who account
for nearly 90 per cent of TB transmissions
globally.
WHO recently commissioned a
study on investing in new TB vaccines, which estimates
that over 25 years, a vaccine that is 50 per cent effective
in preventing disease among young people and adults could
avert up to 76 million TB cases.
Furthermore, every
dollar invested in a 50 per cent effective vaccine could
generate an economic return of $7 in terms of averted health
costs and increased productivity. Additionally, some 8.5
million lives could be saved, as well as $6.5 billion in
costs faced by TB-affected households, especially for the
poorest and most vulnerable.
Meanwhile, a vaccine with
75 per cent efficacy could avert up to 110 million new TB
cases and 12.3 million deaths.
Countries will meet
later this year for a UN High-Level Meeting to review
progress on commitments made in a 2018 political declaration
on the fight against TB. WHO described the event as an
important opportunity to correct setbacks in the response to
the virus, which includes the urgent development and
delivery of new TB
vaccines.
© Scoop Media



















Discussion about this post